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Invasive meningococcal disease incidence in England 
declined from 1.93/100,000 persons (1,016 cases) in 
2010–11 to 0.95/100,000 (530 cases) in 2018–19 and 
0.74/100,000 in 2019–20 (419 cases). During national 
lockdown for the coronavirus disease pandemic (April–
August 2020), incidence was 75% lower than during 
April–August 2019.
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Neisseria meningitidis is a major global cause of bacterial meningitis and septicemia (1). Six se-
rogroups (A, B, C, W, X, Y) are responsible for most 
invasive meningococcal disease (IMD) cases (1). In 
the United Kingdom, implementation of serogroup 
C (MenC) meningococcal conjugate vaccine in 1999 
led to sustained declines in MenC disease (2). In 
August 2015, an emergency adolescent MenACWY 
immunization program for persons 13–18 years of 
age and new university students was implemented 
to control a national outbreak of a hypervirulent 
MenW strain belonging to sequence type 11 clonal 
complex (MenW:cc11) (3). In September 2015, the 
United Kingdom became the first country to add a 
protein-based meningococcal B vaccine, 4CMenB, 
into the national infant immunization program (4). 
Both programs have reduced IMD caused by the re-
spective vaccine serogroups (5). 
Since December 2019, the novel coronavirus 
(COVID-19) pandemic has led to major changes in the 
epidemiology of bacterial and viral infections world-
wide (Brueggemann AB et al., unpub. data, https://
www.medrxiv.org/content/10.1101/2020.11.18.2022
5029v1). We report IMD incidence in England during 
2011–2020, including the impact of a national lock-
down to control the spread of severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2).
Public Health England (PHE) conducts nation-
al surveillance of IMD (6) and SARS-CoV-2 (7) in 
England. IMD incidence was highest, 1.93 cas-
es/100,000 population (1,016 total cases), during the 
2010–11 academic year (September–August) and de-
clined to 1.15 cases /100,000 population for 2013–14 
(617 cases) before increasing to 1.51 cases /100,000 
population (825 cases) in 2015–16 (Figure). Adoles-
cent MenACWY and infant 4CMenB immunization 
programs in 2015 led to additional annual declines in 
IMD incidence, to 0.95 cases /100,000 population (530 
cases) in 2018–19 (incidence rate ratio [IRR] 0.63 [95% 
CI 0.56–0.70] for 2018–19 vs. 2015–16 ). Incidence fur-
ther declined during the 2019–20 pandemic year (419 
cases; 0.74 cases /100,000 population; IRR 0.49 [95% 
CI 0.44–0.56] for 2019–20 vs. 2015–16). IMD cases de-
clined for all serogroups from 2015–16 to 2019–20: 
MenB by 38% (from 452 to 279 cases), MenC by 41% 
(41 to 24 cases), MenW by 68% (218 to 70 cases) and 
MenY by 66% (108 to 37 cases) (Appendix Figure 1, 
https://wwwnc.cdc.gov/EID/article/27/9/20-
4866-App1.pdf). 
IMD cases declined after the national COVID-19 
lockdown on March 23, 2020, and remained low during 
April–August 2020 (Appendix Figure 2). During 2018–
19, PHE received 12,628 clinical samples from patients 
with suspected IMD; of these, 462 (4%) tested positive 
for N. meningitidis. These totals were 9,968 specimens, 
401 (4%) positive, during 2019–20 (21% fewer cases). 
During April–August 2020, a total of 50 (1.8%) of 2,808 
samples tested positive for N. meningitidis, compared 
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Figure. Cases of invasive meningococcal disease, by academic 
year, England, 2015–2020. Men, meningococcal conjugate 
vaccine (by serogroup).
with 134 (2.7%) of 5,025 samples during the same pe-
riod in 2019 (p = 0.016). Combining culture-confirmed 
and PCR-confirmed cases, IMD incidence was 75% 
lower (IRR 0.25, 95% CI 0.18–0.35) during April–Au-
gust 2020 than during April–August 2019 (Table). 
In contrast, IMD incidence during September 2019–
March 2020 (the 7 months before national lockdown) 
was similar to that for September 2018–March 2019 
(IRR 1.06, 95% CI 0.91–1.23). Declines were observed 
for all age groups and serogroups (Appendix Table). 
During lockdown, compared with the same period 
during the previous year, MenB was overrepresented 
(33/45 [73%] vs. 104/179 [58%] cases), whereasMenW 
(5/45 [11%] vs. 42/179 [23%] cases) and MenY (0/45 
[0%] vs. 16/179 [9%] cases) were underrepresented 
(Appendix Table, Figure 1).
A total of 45 IMD cases were diagnosed during 
April–August 2020. The median age of patients was 
67 (interquartile range 20–85) years. Linkage with 
national SARS-CoV-2 data identified 2 patients with 
IMD who were also positive for SARS-CoV-2 by re-
verse transcription PCR; both were <90 days of age 
with late-onset MenB meningitis, and 1 died. Menin-
gitis (with or without septicemia) was proportionally 
more frequent during the lockdown months com-
pared with the same period in 2019 (27/45 [60%] v. 
71/179 [39.7%] cases; p = 0.014). Three (6.7%) of the 45 
patients died within 28 days of diagnosis: the infant 
with co-infection, an adult with MenB meningitis, 
and an older adult with MenB septicemia.
Limitations of our study include limited clinical 
data collected for undiagnosed IMD cases. Cases and 
case-fatality rates during the lockdown period might 
also be underestimated if some patients died of IMD at 
home because they did not seek medical help earlier as a 
result of the stay at home messaging during lockdown.
In summary, IMD incidence in England has been 
declining since the early 2000s (8) because of the MenC 
immunization program and natural trends in MenB 
disease and further declined because of 2 new menin-
gococcal immunization programs. National lockdown 
in March 2020 led to a 75% reduction in cases com-
pared with the same period in the previous year, with 
MenB cases overrepresented. Declines in IMD cases 
after national lockdown were also reported in France 
(9), which is reassuring because viral infections are 
known to precede IMD; therefore, SARS-CoV-2 could 
potentially have increased the risk of secondary bacte-
rial infections. Our findings do not support wider vac-
cination against IMD during the COVID-19 pandemic.
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Table. Confirmed cases of meningococcal disease during April–August 2019 and April–August 2020, England* 
Category April–Aug 2019, no. (%) April–Aug 2020, no. (%) RR (95% CI) 
Group    
 Total (N) 179 45 0.25 (0.18–0.35) 
 MenB 104 (58) 33 (73) 0.32 (0.21–0.47) 
 MenC 14 (8) 5 (11) 0.36 (0.13–0.99) 
 MenW 42 (23) 5 (11) 0.12 (0.05–0.30) 
 MenY 16 (9) 0 0 
 Other 3 (2) 2 (4) 0.67 (0.11–3.97) 
Age group, y 
 Total 179 45 0.25 (0.18–0.35) 
 <5 39 (22) 17 (38) 0.44 (0.25–0.78) 
 5–14 20 (11) 4 (9) 0.2 (0.07–0.58) 
 15–24 24 (13) 4 (9) 0.17 (0.06–0.48) 
 25–64 53 (30) 14 (31) 0.26 (0.15–0.47) 
 >65 43 (24) 6 (13) 0.14 (0.06–0.32) 
*The numbers of typeable strains during the specified time frame by age group are shown. RR, relative risk. 
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Appendix Table. Demographic, clinical, and microbiological information comparing cases of meningococcal disease during April–






χ2 test of independence 
p value 





 Female 92 (51%) 27 (60%) 
 
 Male 87 (49%) 18 (40%)  
Age group, y 
  
0.175 
 <5 39 (22%) 17( 38%) 
 
 5–14 20 (11%) 4 (9%) 
 
 15–24 24 (13%) 4 (9%) 
 
 25–64 53 (30%) 14 (31%) 
 





 MenB 104 (58%) 33 (73%) 
 
 MenC 14 (8%) 5 (11%) 
 
 MenW 42 (23%) 5 (11%) 
 
 MenY 16 (9%) 0 (0%) 
 





 Meningitis 27 (15%) 13 (29%) 
 
 Septicemia 87 (49%) 15 (33%) 
 
 Meningitis and septicemia 44 (25%) 14 (31%) 
 
 Pneumonia 5 (3%) 0 (0%) 
 





 Culture positive 76 (42%) 12 (27%) 
 
 PCR positive 61 (34%) 25( 56%) 
 
 Culture/PCR positive 42 (23%) 8 (18%) 
 
Death within 28 d 13 (7%) 3 (7%) 0.89 
 
 
Page 2 of 3 
 
Appendix Figure 1. Annual number of cases of invasive meningococcal disease, England, 2015–2020: 
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Appendix Figure 2. Total numbers of cases of invasive meningococcal disease, England, 2015–2020. 
